AnaptysBio (NASDAQ:ANAB) Director Magda Marquet Sells 11,000 Shares of Stock

AnaptysBio, Inc. (NASDAQ:ANAB) Director Magda Marquet sold 11,000 shares of AnaptysBio stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $48.23, for a total value of $530,530.00. Following the transaction, the director owned 9,930 shares of the company’s stock, valued at $478,923.90. This represents a 52.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

AnaptysBio Trading Down 1.4%

ANAB opened at $45.68 on Friday. The stock’s fifty day simple moving average is $43.71 and its 200 day simple moving average is $32.32. AnaptysBio, Inc. has a 1-year low of $12.21 and a 1-year high of $52.47. The stock has a market cap of $1.26 billion, a PE ratio of -16.20 and a beta of 0.32.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, beating the consensus estimate of ($1.06) by $1.58. The firm had revenue of $76.32 million for the quarter, compared to the consensus estimate of $15.83 million. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. Equities analysts forecast that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

AnaptysBio announced that its Board of Directors has approved a stock repurchase program on Friday, November 21st that authorizes the company to buyback $100.00 million in shares. This buyback authorization authorizes the biotechnology company to reacquire up to 9.6% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

ANAB has been the topic of several research analyst reports. Barclays lowered their price target on shares of AnaptysBio from $70.00 to $55.00 and set an “overweight” rating on the stock in a report on Wednesday, December 17th. UBS Group started coverage on AnaptysBio in a research note on Wednesday, January 7th. They set a “buy” rating and a $70.00 target price on the stock. Wall Street Zen raised AnaptysBio from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 16th. Wells Fargo & Company upped their price objective on AnaptysBio from $51.00 to $81.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Finally, HC Wainwright lowered their price objective on AnaptysBio from $52.00 to $51.00 and set a “buy” rating on the stock in a research report on Monday, November 24th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, AnaptysBio has a consensus rating of “Moderate Buy” and a consensus price target of $60.40.

Hedge Funds Weigh In On AnaptysBio

A number of hedge funds have recently added to or reduced their stakes in the stock. Larson Financial Group LLC raised its holdings in AnaptysBio by 54.6% in the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 473 shares in the last quarter. Rhumbline Advisers increased its position in shares of AnaptysBio by 2.7% in the first quarter. Rhumbline Advisers now owns 30,903 shares of the biotechnology company’s stock worth $574,000 after purchasing an additional 826 shares during the period. Bessemer Group Inc. raised its stake in AnaptysBio by 950.0% in the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 1,292 shares in the last quarter. Corton Capital Inc. lifted its position in AnaptysBio by 12.2% during the second quarter. Corton Capital Inc. now owns 12,004 shares of the biotechnology company’s stock worth $266,000 after purchasing an additional 1,305 shares during the period. Finally, Tower Research Capital LLC TRC grew its stake in AnaptysBio by 175.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after buying an additional 1,377 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.